Research programme: anti-inflammatories - TransCell Therapeutics
Latest Information Update: 31 Mar 2011
At a glance
- Originator TransCell Therapeutics
- Class Peptides
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Age-related macular degeneration; Atopic dermatitis; Crohn's disease; Diabetic retinopathy; Hepatitis; Inflammatory bowel diseases; Ocular inflammation; Psoriasis; Scleroderma; Sepsis; Ulcerative colitis
Most Recent Events
- 27 Aug 2003 Preclinical trials in Age-related macular degeneration in USA (Ophthalmic)
- 27 Aug 2003 Preclinical trials in Atopic dermatitis in USA (Topical)
- 27 Aug 2003 Preclinical trials in Crohn's disease in USA (PO)